On April 16, 2025, Atea Pharmaceuticals entered an agreement with Radoff-JEC Signatories, resulting in the appointment of Howard H. Berman as a Class III director and the retirement of Franklin Berger in 2027; on April 17, 2025, they reported $425.4 million in cash and announced a $25 million share repurchase program.